{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"OG000","title":"LY2523355"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"End of study treatment up to 30-days post-study treatment discontinuation","title":"Number of Participants Who Died Due to Unknown Causes During the 30-Day Post-Study Treatment Follow-Up","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}